State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou 215123, China.
Int J Mol Sci. 2022 Feb 19;23(4):2316. doi: 10.3390/ijms23042316.
Non-small-cell lung cancer (NSCLC) has a high incidence and poses a serious threat to human health. However, the treatment outcomes of concurrent chemoradiotherapy for non-small-cell lung cancer are still unsatisfactory, especially for high grade lesions. As a new cancer treatment, heavy ion radiotherapy has shown promising efficacy and safety in the treatment of non-small-cell lung cancer. This article discusses the clinical progress of heavy ion radiotherapy in the treatment of non-small-cell lung cancer mainly from the different cancer stages, the different doses of heavy ion beams, and the patient's individual factors, and explores the deficiency of heavy ion radiotherapy in the treatment of non-small-cell lung cancer and the directions of future research, in order to provide reference for the wider and better application of heavy ion radiotherapy in the future.
非小细胞肺癌（NSCLC）发病率高，严重威胁人类健康。然而，非小细胞肺癌同步放化疗的治疗效果仍不理想，特别是对于高级别病变。重离子放疗作为一种新的癌症治疗方法，在非小细胞肺癌的治疗中显示出良好的疗效和安全性。本文主要从不同癌症分期、不同重离子束剂量以及患者个体因素等方面探讨重离子放疗在非小细胞肺癌治疗中的临床进展，探讨重离子放疗在非小细胞肺癌治疗中的不足及未来研究方向，以期为重离子放疗在未来更广泛、更好的应用提供参考。
